Imagine a doctor trying to fix a plumbing leak in a dark room without knowing where the clog is. This technology acts like a high-tech flashlight and map, using AI to show exactly what a blood clot looks like from a standard scan. It helps doctors pick the right tool for the job immediately, rather than guessing with a one-size-fits-all approach.
Stroke care currently relies on a one-size-fits-all approach because physicians lack real-time, patient-specific data about blood clots. This delay and lack of precision lead to high mortality and disability rates.
An AI-powered software platform that automatically analyzes blood clots from standard CT scans and a cloud-agnostic integration layer for hospitals.
If you are a software provider dealing with slow diagnostic workflows — this project developed an AI-powered platform that derives advanced diagnostic information from routine scans. This allows for faster treatment decisions in time-critical emergencies.
If you are a hospital group dealing with high disability rates in stroke patients — this project developed a regulatory-ready solution that reduces the time to intervention. This helps prevent the loss of 22 healthy life-days per minute of delay.
If you are a cloud provider dealing with rigid medical data silos — this project developed a scalable, cloud-agnostic platform. It demonstrates a pathway for seamless integration into existing hospital workflows.
Based on available project data, specific pricing or cost details are not provided.
Yes, the project developed a scalable, cloud-agnostic platform designed for widespread clinical adoption and seamless integration into hospital workflows.
Based on available project data, the project has developed a near-market, regulatory-ready solution, but specific licensing terms are not listed.
The platform is built to be cloud-agnostic and was validated to ensure seamless integration into existing hospital workflows.
The project period ran from 2023-03-01 to 2025-02-28, resulting in a near-market solution.
The project is led by a single Dutch SME, NICO-LAB BV, which holds a 100% industry ratio. This lean structure suggests a highly focused commercial drive, moving directly from development to a near-market solution without the overhead of academic partners.
Contact NICO-LAB BV in the Netherlands for licensing and integration details.
Contact us to explore partnership opportunities with NICO-LAB BV for AI-driven stroke diagnostics.
